Health care is inundated with scheduling conflicts, financial burdens, and misdiagnosis of medical issues. To combat these human costs, medical personnel are looking at artificial intelligence to strengthen decisions in diagnoses of cancers.
In 2021, the FDA began focusing on computer algorithms. Allowing companies to pursue technology models to determine and diagnose cancer and the relative stage and path it may be on within a patient. The company Paige creates an AI tool that siphons through prostate biopsy images and compares them to what could be potential prostate cancer. Paige claims its AI into prostate biopsies has diminished errors by 70%, written in a public medical review. Various other companies, such as Nucleai and PathAI are also strengthening their tools for pathology. Radiologists have the approval from the FDA to start using AI algorithms in CT scans, colonoscopy, and mammogram imagery.
There is a bit of skepticism from the medical field about artificial algorithms giving correct information. Some tend to feel the technology is in its infancy stages and may not be effective. Treatment that is deemed unnecessary or creates false assumptions.
While initial tests of this new AI tech have been highly successful, medical scientists have yet to see its effectiveness on larger mass populations.
We may see in the future every medical department using AI when assessing patient care.